

# UODB - UCSF Urologic Oncology Publications



## Urologic Outcomes Database (UODB) and related outcomes studies

Go to [HOME](#) page

### JOURNAL ARTICLES BY YEAR OF PUBLICATION

Click PubMed ID for copyright-compliant access to publications via UC-elinks

#### 2003

1. Cooperberg MR, Master VA, Carroll PR. Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. *J Urol.* 2003 Aug;170(2 Pt 1):512-5. [PMID: 12853811](#)

#### 2004

2. Anast JW, Stoller ML, Meng MV, Master VA, Mitchell JA, Bassett WW, Kane CJ. Differences in complications and outcomes for obese patients undergoing laparoscopic radical, partial or simple nephrectomy. *J Urol.* 2004 Dec;172(6 Pt 1):2287-91. [PMID: 15538250](#)

3. Kane CJ, Mitchell JA, Meng MV, Anast J, Carroll PR, Stoller ML. Laparoscopic partial nephrectomy with temporary arterial occlusion: description of technique and renal function outcomes. *Urology.* 2004;63(2):241-6. [PMID: 14972462](#)

#### 2005

4. Master VA, Chi T, Simko JP, Weinberg V, Carroll PR. The independent impact of extended pattern biopsy on prostate cancer stage migration. *J Urol.* 2005 Nov;174(5):1789-93; discussion 1793. [PMID: 16217288](#)

5. Master VA, Gottschalk AR, Kane CJ, Carroll PR. Management of isolated renal fossa recurrence following radical nephrectomy. *J Urol.* 2005 Aug;174(2):473-7. Discussion 477. [PMID: 16006867](#)

#### 2006

6. Eisenberg MS, Meng MV, Master VA, Stoller ML, Rini BI, Carroll PR, Kane CJ. Laparoscopic versus open cytoreductive nephrectomy in advanced renal-cell carcinoma. *J Endourol.* 2006 Jul; 20(7):504-8. [PMID: 16859465](#)

## 2008

7. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. *Nat Clin Pract Urol*. 2008 May;5(5):277-83. PMID: [18285752](#)
8. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Carroll, P.R. Active surveillance for the management of prostate cancer in a contemporary cohort. *Cancer*. 2008 Jun 15;112(12):2664-70; comment 2631-4. PMID: [18433013](#)
9. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. *Cancer*. 2008 Apr 15;112(8):1650-9. PMID : [18306379](#)

## 2009

10. Conti SL, Dall'Era MA, Fradet V, Cowan JE, Simko, J, Carroll PR. Pathologic outcomes in men meeting criteria for active surveillance of prostate cancer. *J Urol*. 2009 Apr;181(4):1628-33; discussion 1633-4. PMID: [19233388](#)  
Comment in: *J Urol*. 2009 Apr;181(4):1534-5.
11. Dall'Era MA, Carroll PR. Outcomes and follow-up strategies for patients on active surveillance. *Curr Opin Urol*. 2009 May; 19(3):258-62. PMID: [19295434](#)
12. Eisenberg ML, Cowan JE, Davies BJ, Carroll PR, Shinohara K. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. *Urol Onc*. 2011;29(2):171-6. Epub 2009 Apr 10. PMID: [19362864](#)
13. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. *J Urol*. 2009 Nov;182(5):2232-41. PMID: [19781717](#)

## 2010

14. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll PR. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. *BJU Int*. 2010;106(11):1734-8. PMID: [20438567](#)
15. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. Adequacy of lymphadenectomy among men undergoing robot assisted laparoscopic radical prostatectomy. *BJU Int*. 2010 Jan;105(1):88-92. PMID: [19549119](#)
16. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. *Eur Urol*. 2010 Apr;57(4):622-9. Epub 2009 Apr 3. PMID: [19375843](#)
17. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. *BJU Int*. 2010;105(9):1237-41. PMID: [19888980](#)

18. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. *Radiology*. 2010 Jul;256(1):176-83. PMID: 20505068
19. Odisho AY, Cooperberg MR, Fradet V, Ahmad AE, Carroll PR. Urologic density and county-level urologic cancer mortality. *J Clin Oncol*. 2010 May 20;28(15):2499-504. PMID: 20406931
20. Porten SP, Cooperberg MR, Carroll PR. The independent value of tumor volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. *BJU Int*. 2010;105(4):472-5. Epub 2009 Aug 13. PMID: 19681901
21. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. Disproportionate presentation of high risk prostate cancer in a safety net health system. *J Urol*. 2010;184(5):1931-6. PMID: 20846693
22. Whitson JM, Carroll PR. Active Surveillance for Early-Stage Prostate Cancer: Defining the Triggers for Intervention. *J Clin Oncol*. 2010 Jun 10;28(17):2807-9. PMID: 20439633

## 2011

23. Carroll PR, Whitson JM, Cooperberg MR. Serum prostate-specific antigen for the early detection of prostate cancer: Always, never, or only sometimes? *J Clin Oncol*. 2011 Feb 1;29(4):345-7. Epub 2010 Dec 28. PMID: 21189396
24. Chan JM, Weinberg V, Magbanua MJ, Sosa E, Simko J, Shinohara K, Federman S, Mattie M, Hughes-Fulford M, Haqq C, Carroll PR. Nutritional supplements, COX-2 and IGF-1 expression in men on active surveillance for prostate cancer. *Cancer Causes Control*. 2011 Jan; 22(1):141-50. Epub 2010 Nov 20. PMID: 21103921
25. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. Outcomes of active surveillance for men with intermediate risk prostate cancer. *J Clin Oncol*. 2011 Jan 10;29(2):228-34. Epub 2010 Nov 29. PMID: 21115873
26. Cooperberg MR, Mallin K, Kane CJ, Carroll PR. Treatment trends for stage I renal cell carcinoma. *J Urol*. 2011;186(2):394-9. PMID: 21679982
27. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. *J Clin Oncol*. 2011 Sep 20;29(27):3669-76. PMID: 21825257
28. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. *BJU Int*. 2011;107(8):1232-7. Epub 2010 Aug 26. PMID: 20804478
29. Magbanua MJ, Roy R, Sosa EV, Weinberg V, Federman S, Mattie MD, Hughes-Fulford M, Simko J, Shinohara K, Haqq CM, Carroll PR, Chan JM. Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation. *PLoS One*. 2011;6(9):e24004. PMID: 21912659
30. McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; the Canary/Early Detection Research Network Prostate Active Surveillance Study Investigators. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. *J Urol*. 2011;186(2):465-9. PMID: 21679996

31. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. *J Clin Oncol*. 2011;29(20):2795-800. PMID: 21632511
32. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. Changes in Cancer Volume in Serial Biopsies of Men on Active Surveillance for Early Stage Prostate Cancer. *J Urol*. 2011;186(5):1825-9. PMID: 21944082 *This paper will be featured for CME credits.*
33. Reese AC, Fradet V, Whitson JM, Davis CB, Carroll PR. Poor agreement of prostate specific antigen doubling times calculated using ultrasensitive versus standard prostate specific antigen values: important impact on risk assessment. *J Urol*. 2011 Dec;186(6):2228-32. PMID: 22014796
34. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. *J Urol*. 2011;185(5):1656-60. PMID: 21419438
35. Whitson JM, Porten SP, Carroll PR. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. *Nat Rev Urol*. 2011 Mar;8(3):124-5. PMID: 21304508
36. Yang G, Whitson JM, Breyer BN, Konety BR, Carroll PR. Oncological and functional outcomes of radical cystectomy and orthotopic bladder replacement in women. *Urology*. 2011;77(4):878-83. PMID: 21215428

## 2012

37. Cooperberg MR, Odisho AY, Carroll PR. Outcomes for radical prostatectomy: is it the singer, the song, or both? *J Clin Oncol*. 2012 Feb 10;30(5):476-8. PMID: 22215744
38. Glass AS, Cooperberg MR, Carroll PR. Early detection of prostate cancer: more information, more clarity. *Eur Urol*. 2012;62(5):753-5. PMID: 22766168
39. Glass AS, Cooperberg MR, Meng MV, Carroll PR. Role of active surveillance in the management of localized prostate cancer. *J Natl Cancer Inst Monogr*. 2012(45):202-6. PMID: 23271774
40. Hilton JF, Blashko SD, Whitson JM, Cowan JE, Carroll PR. The impact of serial biopsies on sexual function in men on active surveillance for prostate cancer. *J Urol*. 2012 Oct;188(4):1252-8. PMID: 22902015
41. Jung AJ, Coakley FV, Shinohara K, Carroll PR, Kurhanewicz J, Cowan JE, Westphalen AC. Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. *Clin Imaging*. 2012 Sep;36(5):547-52. PMID: 22920360
42. Reese AC, Cowan JE, Brajtbord JS, Harris CR, Carroll PR, Cooperberg MR. The quantitative Gleason score improves prostate cancer risk assessment. *Cancer*. 2012;118(24):6046-54. PMID: 22674220
43. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason Score (GS)  $\leq 6$  have the potential to metastasize to lymph nodes? *Am J Surg Pathol*. 2012;36(9):1346-52. PMID: 22531173

44. Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. *BJU Int.* 2012;110(1):50-5. Epub 2011 Nov 11. PMID: 22077660

## 2013

45. Bauer SR, Richman EL, Sosa E, Weinberg V, Song X, Witte JS, Carroll PR, Chan JM. Antioxidant and vitamin E transport genes and risk of high-grade prostate cancer and prostate cancer recurrence. *Prostate.* 2013 Dec;73(16):1786-95. PMID: 24038157

46. Cary KC, Cowan JE, Sanford M, Shinohara K, Perez N, Chan JM, Meng MV, Carroll PR. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. *Eur Urol.* 2014 Aug 66(2):337-42. Epub 2013 Sep 9. PMID: 24035632

47. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. *J Clin Oncol.* 2013 Apr 10;31(11):1428-34. PMID: 23460710

48. Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR. Active surveillance: Does serial prostate biopsy increase histological inflammation? *Prostate Cancer Prostatic Dis.* 2013;16(2):165-9. PMID: 23318528

49. Hawley S, Fazli L, McKenney JK, Simko J, Troyer D, Nicolas M, Newcomb LF, Cowan JE, Crouch L, Ferrari M, Hernandez J, Hurtado-Coll A, Kuchinsky K, Liew J, Mendez-Meza R, Smith E, Tenggara I, Zhang X, Carroll PR, Chan JM, Gleave M, Lance R, Lin DW, Nelson PS, Thompson IM, Feng Z, True LD, Brooks JD. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. *Adv Anat Pathol.* 2013 Jan;20(1):39-44. PMID: 23232570

50. Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll PR, Feng Z, Gleave ME, Lance RS, Sanda MG, Thompson IM, Wei JT, Nelson PS; Canary Prostate Active Surveillance Study Investigators. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. *Clin Cancer Res.* 2013 May 1;19(9):2442-50. PMID: 23515404

51. Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR. Benign prostate glandular tissue at radical prostatectomy surgical margins. *Urology.* 2013;82(1):154-9. PMID: 23522995

52. Ornish D, Lin J, Chan JM, Epel E, Kemp C, Weidner G, Marlin R, Fenda SJ, Magbanua MJ, Daubenmier J, Estay I, Hills NK, Chainani-Wu N, Carroll PR, Blackburn EH. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. *Lancet Oncol*. 2013 Oct;14(11):1112-20. PMID: 24051140
53. Punnen S, Meng MV, Cooperberg MR, Greene KL, Cowan JE, Carroll PR. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? *BJU Int*. 2013 Aug;112(4):E314-20. PMID: 23451984
54. Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. *BJU Int*. 2013. Jul;112(2):E67-75. PMID: 23795800
55. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. Factors associated with downgrading in patients with high grade prostate cancer. *Urol Oncol*. 2013 May; 31(4):442-7. Epub 2011 Apr 8. PMID: 21478037

## 2014

56. Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. *J Natl Compr Canc Netw*. 2014 Sep;12(9):1211-9. PMID: 25190691
57. Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T, Chan JM, Li J, Cowan JE, Tsiatis AC, Cherbavaz DB, Pelham RJ, Tenggara-Hunter I, Baehner FL, Knezevic D, Febbo PG, Shak S, Kattan MW, Lee M, Carroll PR. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol*. 2014 Sep;66(3):550-60. PMID: 24836057  
Reply to letter to the editor: PMID: 25150174
58. Glass AS, Hilton JF, Cowan JE, Washington SL, Carroll PR. Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. *Urology*. 2014 Jan;83(1):33-9. Epub 2013 Nov 15. PMID: 24246319
59. Punnen S, Cary KC, Glass AS, Cowan JE, Carroll PR. Autologous retro-pubic urethral sling: a novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. *J Robotic Surg*. 2014;8:99–104 PMID: None
60. Wang SY, Cowan JE, Cary KC, Chan JM, Carroll PR, Cooperberg MR. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. *BJU Int*. 2014 Dec;114(6b):E18-24. PMID: 24712895
61. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Billewicz R. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. *PLoS One*. 2014 Jun 3;9(6):e98597. PMID: 2489317

## 2015

62. Filippou P, Welty CJ, Cowan JE, Perez N, Shinohara K, Carroll PR. Immediate Versus Delayed Radical Prostatectomy: Updated Outcomes Following Active Surveillance of Prostate Cancer. *Eur Urol*. 2015 Sep;68(3):458-63. PMID: [26138041](#)
63. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. Untreated Gleason grade progression on serial biopsies during prostate cancer active surveillance: clinical course and pathological outcomes. *J Urol*. 2015 Jul;194(1):85-90. PMID: [25623742](#)
64. Jalloh M, Leapman MS, Cowan JE, Shinohara K, Greene KL, Roach M 3rd, Chang AJ, Chan JM, Simko JP, Carroll PR. Patterns of local failure following radiation therapy for prostate cancer. *J Urol*. 2015 Oct;194(4):977-82. PMID: [25983194](#)
65. Cancer Genome Atlas Research Network (TCGA). The molecular taxonomy of primary prostate cancer. *Cell*. 2015 Nov 5;163(4):1011-25. PMID: [26544944](#)
66. Welty CJ, Cowan JE, Nguyen H, Shinohara K, Perez N, Greene KL, Chan JM, Meng MV, Simko JP, Cooperberg MR, Carroll PR. Extended follow-up and risk factors for disease reclassification from a large active surveillance cohort for localized prostate cancer. *J Urol*. 2015 Mar;193(3):807-11. Epub 2014 Sep 24. PMID: [25261803](#)

## 2016

67. Eltemamy MM, Leapman MS, Cowan JE, Westphalen A, Shinohara K, Carroll PR. Serial anatomic prostate ultrasound imaging during prostate cancer active surveillance. *J Urol*. 2016 Sep;196(3):727-33. PMID: [27117443](#)
68. Kenfield SA, Batista JL, Jahn JL, Downer MK, Van Blarigan EL, Sesso HD, Giovannucci EL, Stampfer MJ, Chan JM. Development and application of a lifestyle score for prevention of lethal prostate cancer. *J Natl Cancer Inst*. 2016;108(3):djv329. PMID: [26577654](#)
69. Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LL, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, Simko JP. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. *J Mol Diagn*. 2016 May;18(3):395-406. PMID: [26945428](#)
70. Leapman MS, Ameli N, Cooperberg MR, Chu C, Hussein A, Shinohara K, Carroll PR. Quantified clinical risk change as an end point during prostate cancer active surveillance. *Eur Urol*. 2017 Sep;72(3):329-332. Epub 2016 May 3. PMID: [27157998](#)
71. Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary Prostate Active Surveillance Study Investigators. Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi-institutional Canary PASS cohort. *J Urol*. 2016 Feb;195(2):313-20. Epub 2015 Aug 29. PMID: [26327354](#)

## 2017

72. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. *J Nucl Med*. 2017 Dec;58(12):1956-61. PMID: 28522741
73. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrence prostate cancer. *EJNMMI Res*. 2017 Sep 19;7(1):77. PMID: [28929350](#)
74. Leapman MS, Ameli N, Shinohara K, Nguyen HG, Meng MV, Cooperberg MR, Carroll PR. Validity of the Cancer of the Prostate Risk Assessment Score Derived from Targeted Biopsy: Modeling Evidence from Ultrasound Lesion-Directed Biopsy. *Clin Genitourin Cancer*. 2017 Feb; 15(1):93-99. Epub 2016 Jul 21. PMID: [27522449](#)
75. Leapman MS, Cowan JE, Nguyen HG, Shinohara K, Perez N, Cooperberg MR, Catalona WJ, Carroll PR. Active surveillance in younger men with prostate cancer. *J Clin Oncol*. 2017. Jun 10;35(17):1898-1904. PMID: [28346806](#)
76. Leapman MS, Westphalen AC, Ameli N, Lawrence HJ, Febbo PG, Cooperberg MR, Carroll PR. Association between a 17-gene prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). *PLoS One*. 2017 Oct 10;12(10). PMID: [29016610](#)
77. Lin DW, Newcomb LF, Brown MD, Sjoberg DD, Dong Y, Brooks JD, Carroll PR, Cooperberg M, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y; Canary Prostate Active Surveillance Study Investigators. Evaluating the Four Kallikrein Panel of the 4K score for prediction of high-grade prostate cancer in men in the Canary Prostate Active Surveillance Study. *Eur Urol*. 2017 Sep;72(3):448-454. Epub 2016 Nov 23. PMID: [27889277](#)
78. Nguyen HG, Punnen S, Cowan JE, Leapman M, Cary C, Welty K, Weinberg V, Cooperberg MR, Meng MV, Greene KL, Garcia M, Carroll PR. A randomized study of intra-operative autologous retropubic urethral sling on urinary control after robotic-assisted radical prostatectomy. *J Urol*. 2017 Feb;197(2):369-375. Epub 2016 Sep 27. PMID: [27693447](#)
79. Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara S, Westphalen AC, Carroll PR. Magnetic resonance imaging-ultrasound fusion biopsy during prostate cancer active surveillance. *Eur Urol*. 2017 Aug;72(2):275-281. Epub 2016 Aug 29. PMID: [27595378](#)
80. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng, MV, Porten SP. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. *Cancer*. 2017 Dec 1;123(23):4574-4582. PMID: [28881475](#)

## 2018

81. Cooperberg MR, Brooks JD, Faino AV, Newcomb LF, Kearns JT, Carroll PR, Dash A, Etzioni R, Fabrizio MD, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW, Zheng Y. Refined analysis of prostate-specific antigen kinetics to predict prostate cancer active surveillance outcomes. *Eur Urol*. 2018 Aug;74(2):211-217. PMID: [29433975](#)



82. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes, M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. The diverse genomic landscape of clinically low-risk prostate cancer. *Eur Urol*. 2018 Oct;74(4):444-452. PMID: [29853306](#)
83. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. Comparative analysis of biopsy upgrading in four prostate cancer active surveillance cohorts. *Annals of Internal Med*. 2018 Jan 2;168(1):1-9. Epub 2017 Nov 28. PMID: [29181514](#)
84. Kearns JT, Faino AV, Newcomb LF, Brooks JD, Carroll PR, Dash A, Ellis WJ, Fabrizio M, Gleave ME, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Zheng Y, Lin DW. Role of surveillance biopsy with no cancer as a prognostic marker for reclassification: results from the Canary Prostate Active Surveillance study *Eur Urol*. 2018 May;73(5):706-712. PMID: [29433973](#)
85. Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. Estimating and comparing cancer progression risks under varying surveillance protocols. *Ann Appl Stat*. 2018 Sep;12(3):1773-1795. PMID: [30627300](#)
86. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. *Eur Urol*. 2018 Nov;74(5):668-675. PMID: [30181067](#)
87. Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. *Eur Urol Oncol*. 2018 Oct;1(5):386-394. PMID: [31158077](#)
88. Nguyen HG, Welty C, Lindquist K, Ngo V, Gilbert E, Bengtsson H, Magi-Galluzzi C, Jean-Gilles J, Yao J, Cooperberg M, Messing E, Klein EA, Carroll PR, Paris PL. Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy. *J Urol*. 2018 Mar;199(3):719-725. Epub 2017 Sep 20. PMID: [28941923](#)
89. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. *Sci Transl Med*. 2018 May 2;10(439). PMID: [29720449](#)
90. Winters-Stone KM, Kenfield SA, Van Blarigan EL, Moe EL, Ramsdill JW, Daniel K, Macaire G, Paich K, Kessler ER, Kucuk O, Gillespie TW, Lyons KS, Beer TM, Broering JM, Carroll PR, Chan JM. Effect of increasing levels of web-based behavioral support on changes in physical activity, diet, and symptoms in men with prostate cancer: protocol for a randomized controlled trial. *JMIR Res Protoc*. 2018 Nov 15;7(11):e11257. PMID: [30442638](#)

## 2019

91. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating the safety of active surveillance: outcomes of deferred radical prostatectomy after an initial period of surveillance. *J Urol*. 2019 Sep;202(3):506-510. PMID: [30958738](#)

92. Cedars BE, Washington SL 3rd, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. Stability of a 17-gene genomic prostate score in serial testing on men on active surveillance for early stage prostate cancer. *J Urol*. 2019 Oct;202(4):696-701. PMID: [30958742](#)
93. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. Correlation of a commercial genomic risk classifier with histologic patterns in prostate cancer. *J Urol*. 2019 Jul;202(1):90-95. PMID: [30810466](#)
94. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable intermediate-risk disease who many not be good candidates for active surveillance. *Prostate Cancer Prostatic Dis*. 2019 Aug 27. Epub ahead of print PMID: [31455846](#)
95. Kenfield SA, Van Blarigan EL, Ameli N, Lavaki E, Cedars B, Pacionek AT, Monroy C, Tantum LK, Newton RU, Signorell C, Suh JH, Zhang L, Cooperberg MR, Chan JM. Feasibility, acceptability, and behavioral outcomes from a technology-enhanced behavioral change intervention (Prostate 8): A pilot randomized controlled trial in men with prostate cancer. *Eur Urol*. 2019 Jun;75(6):950-958. PMID: [30638635](#)
96. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. Genomic Prostate Score, PI-RADSv2, and progression in men with prostate cancer on active surveillance. *J Urol*. 2019 Feb;201(2):300-307. PMID: [30179620](#) Epub 2018 Sep 1.
97. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology for Men on Active Surveillance. *J Urol*. 2019 Oct;202(4):702-709. PMID: [31026214](#)
98. Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelsson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. *Cancer*. 2019 Oct 22. **Epub ahead of print.** PMID: [31639200](#)
99. Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). *Prostate Cancer Prostatic Dis*. 2019 Sep;22(3):438-44. PMID: [30664734](#)
100. Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL 3rd, Herlemann A, Carroll PR, Cooperberg MR. Automating the Capture of Structured Pathology Data for Prostate Cancer Care and Research. *JCO Clin Informatics* 2019 Jul;(3):1-8. PMID: [31314550](#)
101. Shenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American race is not associated with risk of reclassification during active surveillance: results from the Canary Prostate Cancer Active Surveillance Study (PASS). *J Urol*. 2019 Oct 25. **Epub ahead of print.** PMID: [31651227](#)

102. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M 3rd, Hope TA, Carroll PR, Feng FY. Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer. *Eur Urol Oncol*. 2019 Nov;2(6):685-690. PMID: [31411984](#)

103. Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. *J Natl Cancer Inst*. 2019 Mar 1;111(3):301-310. Epub 2018 Oct 13. PMID: [30321406](#)

## 2020

104. Washington SL 3rd, Baskin AS, Ameli N, Nguyen HG, Westphalen AC, Shinohara K, Carroll PR. MRI-based prostate-specific antigen density predicts Gleason score upgrade in an active surveillance cohort. *AJR Am J Roentgenol*. 2020 Jan 8:1-5. **Epub ahead of print** PMID: [31913068](#)

## DOD TIA

Belkora J, Chan JM, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. *Cancer Med*. 2020 Jan;9(1):125-132. Epub 2019 Nov 12. PMID: [31714037](#)

## GAP3 consortium

Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, Weerakoon M, Bokhorst LP, Roobol MJ; Movember GAP3 consortium. Active surveillance for prostate cancer: a narrative review of clinical guidelines. *Nat Rev Urol*. 2016 Jan 27. PMID: [26813955](#)

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure. *Nat Rev Urol*. 2017 May;14(5):312-322. PMID: [28290462](#)

Bruinsma SM, Zhang L, Roobol MJ, Bangma CH, Steyerberg EW, Nieboer D, Van Hemelrijck M; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3)

consortium. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date. *BJU Int.* 2018 May;121(5):737-744. PMID: [29247473](#)

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium. Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 consortium. *Eur Urol.* 2019 Mar;75(3):523-531. PMID: [30385049](#)

## Related studies, reviews, editorials

Anwar M, Westphalen AC, Jung AJ, Noworolski SM, Simko JP, Kurhanewicz J, Roach M 3rd, Carroll PR, Coakley FV. Role of endorectal MR imaging and MR spectroscopic imaging in defining treatable intraprostatic tumor foci in prostate cancer: Quantitative analysis of imaging contour compared to whole-mount histopathology. *Radiother Oncol.* 2014 Feb;110(2):303-8. PMID: [24444524](#)

Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schroder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol.* 2013 Mar;85(3):295-302. Epub 2012 Aug 9. Review. PMID: [22878262](#)

Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active surveillance for low-risk prostate cancer: developments to date. *Eur Urol.* 2015 Apr;67(4):646-8. PMID: [25435266](#)

Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A. Who and when should we screen for prostate cancer? Interviews with key opinion leaders. *BMC Med.* 2015 Nov 27;13(1):288. PMID: [26612204](#)

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Kim S, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Moses KA, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenkle P, Vickers AJ, Wake R, Shead DA, Freedman-Cass DA. NCCN Guideline Insights: Prostate Cancer Early Detection, Version 2.2016. *J Natl Compr Canc Netw.* 2016 May;14(5):509-19. PMID: [27160230](#)

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Sprenke P, Vickers AJ, Wake R, Shead DA, Freedman-Cass D. Prostate Cancer Early Detection: Version 2.2015. *J Natl Compr Canc Netw.* 2015 Dec;13(12):1534-61. PMID: [26656522](#)

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF. The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. *Eur Urol*. 2019 May 23. **Epub ahead of print** PMID: [31128968](#)

Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M 3rd. Long-term outcomes following radiation therapy for prostate cancer patients with lymph node metastasis at diagnosis treated with and without surgery. *Am J Clin Oncol*. 2016 Apr; 39(2):167-72. PMID: [24441584](#) Epub 2014 Jan 16.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. *Eur Urol*. 2012 Dec;62(6):976-83. PMID: [22698574](#)

Dall'Era M, Carroll P. What is the optimal way to select candidates for active surveillance of prostate cancer? *J Urol*. 2015 Sep;194(3):615-6. PMID: [26079332](#)

Jalloh M, Cooperberg MR. Implementation of PSA-based active surveillance in prostate cancer. *Biomark Med*. 2014 Jun;8(5):747-53. PMID: [25123041](#)

Leapman MS, Carroll PR. New genetic markers for prostate cancer. *Urol Clin North Am*. 2016 Feb;43(1):7-15. Epub 2015 Oct 31. PMID: [26614025](#)

Leapman MS, Carroll PR. Immediate androgen deprivation: for all or for some? *Lancet Oncol*. 2016 Jun;17(6):683-684. PMID: [27155739](#)

Leapman MS, Carroll PR. What is the best way not to treat prostate cancer? *Urol Oncol*. 2017 Feb;35(2):42-50. Epub 2016 Oct 13. PMID: [27746147](#)

Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. *Eur Urol*. 2014 Jun;65(6):1046-55. PMID: [24439788](#)

Mallin K, David KA, Carroll PR, Milowsky MI, Nanus DM. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). *J Urol*. 2011 May;185(5):1631-6. PMID: [21419456](#)

Masic S, Washington SL 3rd, Carroll PR. Management of intermediate-risk prostate cancer with active surveillance: never or sometimes? *Curr Opin Urol*. 2017 May;27(3):231-237. PMID: [28234748](#)

Messing EM, Albertsen P, Andriole GL Jr, Carroll PR, Klein EA. The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing. *Urol Oncol*. 2012 Jan;30(1):117-9. PMID: [22243597](#)

Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P, Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: Results from the SEARCH database. *Cancer*. 2014 Jan 15;120(2):197-204. Epub 2013 Oct 11. PMID: [24127391](#)

Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, Costello A, Eastham JA, Ficarra V, Guazzoni G, Menon M, Novara G, Patel VR, Stolzenburg JU, Van der Poel H, Van Poppel H, Mottrie A. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. *Eur Urol*. 2012 Sep;62(3):368-81. PMID: [22763081](#)

Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations - a report of a European School of Oncology task force. *Eur Urol*. 2017 Apr;71(4):648-655. Epub 2016 Jun 24. PMID: [27349615](#)

Muglia VF, Westphalen AC, Wang ZJ, Kurhanewicz J, Carroll PR, Coakley FV. Endorectal MRI of prostate cancer: incremental prognostic importance of gross locally advanced disease. *AJR Am J Roentgenol*. 2011 Dec;197(6):1369-74. PMID: [22109291](#)

Porten SP, Cooperberg MR. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. *Curr Opin Urol*. 2012 Sep;22(5):385-9. PMID: [22842681](#)

Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, Nguyen H, Zhao SG, Mehra R, Glass AG, Lam LLC, Chelliserry J, du Plessis M, Choerung V, Aranes M, Kolisnik T, Margrave J, Alter J, Jordan J, Buerki C, Yousefi K, Haddad Z, Davicioni E, Trabulsi EJ, Loeb S, Tewari A, Carroll PR, Weinmann S, Schaeffer EM, Klein EA, Karnes RJ, Feng FY, Nguyen PL. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. *J Clin Oncol*. 2018 Feb 20;36(6):581-590. Epub 2018 Nov 29. PMID: [29185869](#)

Tasian GE, Cooperberg MR, Potter MB, Cowan JE, Greene KL, Carroll PR, Chan JM. PSA screening: determinants of primary-care physician practice patterns. *Prostate Cancer Prostatic Dis*. 2012;15(2):189-94. Epub 2011 Nov 29. PMID: [22343837](#)

Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. *Urol Oncol*. 2012 Mar-Apr;30(2):155-60. Epub 2010 Aug 25. *Urology*. 2013 Jul;82(1):53-59. PMID: [20800514](#)

Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, Valdagni R, Bellardita L. Setting an agenda for assessment of health-related quality of life among men with prostate cancer on active surveillance: a consensus paper from a European School of Oncology task force. *Eur Urol*. 2017 Feb;71(2):274-280. Epub 2016 Oct 6. PMID: [27720532](#)

Welty CJ, Carroll PR. The ongoing need for improved risk stratification and monitoring for those on active surveillance for early stage prostate cancer. *Eur Urol*. 2014 Jun;65(6):1032-3. PMID: [24636678](#)

Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. *Prostate Cancer Prostatic Dis*. 2012 Mar;15(1):100-5. Epub 2011 Nov 1. PMID: [22042252](#)

## **TCGA**

Cancer Genome Atlas Research Network. The Molecular Taxonomy of Primary Prostate Cancer. *Cell*. 2015 Nov 5;163(4):1011-25. PMID: [26544944](#)

## **Urologic Disease of America Project**

Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR; the Urologic Disease of America Project. Updated trends in imaging use in men diagnosed with prostate cancer. *Prostate Cancer Prostatic Dis*. 2014 Sep;17(3):246-51. PMID: [24819235](#)

Go to [HOME](#) page